B

BriaCell Therapeutics Corp
D

BCTX

12.270
USD
-0.30
(-2.39%)
مغلق
حجم التداول
3,481
الربح لكل سهم
-164
العائد الربحي
-
P/E
-0
حجم السوق
21,535,187
الأخبار المقالات

العنوان: Briacell Therapeutics Corp NEW

القطاع: Healthcare
الصناعة: Biotechnology
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.